ERN2

Serine/threonine-protein kinase/endoribonuclease IRE2 · Q76MJ5 · ERN2 on Sugi Atlas →

2,406 patent compounds predicted against ERN2, 1,717 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Dabrafenib (SCHEMBL806377)	1.00	1/20
Azd-8186 (SCHEMBL1636956)	1.00	1/20
Azd-8186 (SCHEMBL1638635)	1.00	1/20
Azd-8186 (SCHEMBL1638875)	1.00	1/20
Golvatinib (SCHEMBL1727298)	1.00	1/20
Golvatinib (SCHEMBL1727167)	0.99	1/20
SCHEMBL2250771	0.96	1/20
Dabrafenib (SCHEMBL1127269)	0.95	1/20
Golvatinib (SCHEMBL1728754)	0.92	1/20
Golvatinib (SCHEMBL93491)	0.91	1/20
Golvatinib (SCHEMBL1727001)	0.91	1/20
SCHEMBL1639623	0.90	1/20
SCHEMBL2193062	0.90	1/20
SCHEMBL2250781	0.89	1/20
SCHEMBL1637208	0.89	1/20
SCHEMBL1638117	0.89	1/20
SCHEMBL1638278	0.89	1/20
SCHEMBL2252237	0.88	1/20
SCHEMBL2255387	0.88	1/20
SCHEMBL1638125	0.86	1/20

Clinical trials — most relevant to ERN2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions	PHASE4	UNKNOWN
Maintenance Hormonal Therapy and DLBCL	PHASE2/PHASE3	NOT_YET_RECRUITING
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity	PHASE2	RECRUITING
Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer	PHASE2	WITHDRAWN
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy	PHASE2	COMPLETED
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula	PHASE2	COMPLETED
Reverse Transcriptase Inhibitors in AGS	PHASE2	COMPLETED
Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors	PHASE1	ACTIVE_NOT_RECRUITING
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients	PHASE1	UNKNOWN
PBA Use for Treatment of ATF6-/- Patients	EARLY_PHASE1	SUSPENDED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
Human Epididymis Protein 4 in Endometrial Carcinoma	nan	COMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes	nan	UNKNOWN
Effect of Protein on Endoplasmic Reticulum Stress	nan	NOT_YET_RECRUITING
EKLF Gene Expression in β-thalassemia	nan	NOT_YET_RECRUITING
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis	nan	COMPLETED
Diagnosis of Inflammatory Bowel Disease	nan	NOT_YET_RECRUITING
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Role of Specific microRNAs in Cluster Headache	nan	RECRUITING
Na+ Channel mRNA Regulation in Heart Failure	nan	COMPLETED
Search for Bovine miRNA Transference to Humans	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ERN2 binder may also engage these)

Protein	Name	Similarity
Q9Z2E3	—	1.000	Q9Z2E3 →
O75064	—	0.987	O75064 →
Q99MQ3	—	0.986	Q99MQ3 →
D3ZWJ9	—	0.985	D3ZWJ9 →
MAP3K6	Mitogen-activated protein kinase kinase kinase 6	0.984	landscape →
Q3T1I9	—	0.984	Q3T1I9 →
Q6ZQA0	—	0.984	Q6ZQA0 →
Q8BYI8	—	0.984	Q8BYI8 →
Q8CIE4	—	0.984	Q8CIE4 →
Q80XI6	—	0.984	Q80XI6 →
Q6PDZ2	—	0.984	Q6PDZ2 →
B5DFG1	—	0.984	B5DFG1 →
Q99ML2	—	0.983	Q99ML2 →
Q8C2S7	—	0.983	Q8C2S7 →
Q8K330	—	0.983	Q8K330 →
Q8BXP5	—	0.983	Q8BXP5 →
A2RU67	—	0.983	A2RU67 →
Q5T124	—	0.983	Q5T124 →
Q2KHV9	—	0.983	Q2KHV9 →
Q91ZJ0	—	0.983	Q91ZJ0 →
E9QAM5	—	0.983	E9QAM5 →
Q8VCC8	—	0.983	Q8VCC8 →
A6NE52	—	0.982	A6NE52 →
A7E3S5	—	0.982	A7E3S5 →
CDC42BPG	Serine/threonine-protein kinase MRCK gamma	0.982	landscape →
Q66HA1	—	0.982	Q66HA1 →
Q8CFK6	—	0.982	Q8CFK6 →
Q9R117	—	0.982	Q9R117 →
A4FU01	—	0.982	A4FU01 →
Q8WWN8	—	0.982	Q8WWN8 →